Melanotan II's 'lasting tan' claims: what the science says

What did @r_sks_ actually say?

The creator, a self-described redhead from Minnesota who says they "couldn't tan," claims that seven months after stopping melanotan II (MT2), they're noticing unusually dark skin on their forearm after just one week of low-UV spring sun exposure. Their interpretation: a heavy tanning base built with MT2 last summer is somehow persisting or priming their skin to tan faster now. They plan to switch to MT1 going forward.

To be fair, they're not claiming MT2 is still in their system. They're making a more nuanced argument, that prior MT2 use may have produced a melanin base that makes subsequent UV-driven tanning easier. That's a specific biological claim, and it deserves a specific biological answer.

Does the science back this up?

Partially, but the creator is missing some important details about why this might be happening. Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds to melanocortin receptors, particularly MC1R and MC4R, and drives melanogenesis, the production of eumelanin (the darker, more UV-protective pigment). The question is whether that effect persists months after stopping.

There's no published human clinical trial specifically studying MT2-induced melanin persistence at seven months post-cessation. What we do know from melanocyte biology is that eumelanin produced in response to either UV or pharmacological stimulation can persist in keratinocytes for weeks to months as cells cycle through. Hadley and Dorr (2006, Peptides) documented that MT2 produces "supraphysiological" melanogenesis that exceeds what UV alone triggers. If the creator built significantly more eumelanin last summer than they would have naturally, it's biologically plausible that their baseline melanin density is still elevated compared to a typical redhead, making them more responsive to spring UV. That said, seven months is a long window, and the creator's skin tone right now is also influenced by factors they haven't accounted for.

What did they get wrong (or right)?

They got the general concept roughly right but overcredited MT2 for what might be a more mundane explanation. Redheads typically express MC1R variants that favor pheomelanin (lighter, less UV-protective pigment) over eumelanin. MT2 can partially override this by forcing eumelanin synthesis regardless of MC1R genotype, as documented in Tatro and Reichlin (1987, Endocrinology). If the creator genuinely shifted their eumelanin-to-pheomelanin ratio last summer, some of that shift could persist.

However, the creator's claim that their forearm "has never been this tan this early" is anecdotal and uncontrolled. They could simply be getting more outdoor sun this spring than in prior years, or their perception of their own skin tone is influenced by expectation. They also don't mention that MT2 carries real safety concerns they're glossing over entirely, including associations with nevi (moles) darkening, blood pressure fluctuation, and nausea. Hauschild et al. (2009, Experimental Dermatology) raised concerns about MT2's potential to activate pre-existing melanocytic lesions. None of that gets airtime here.

What should you actually know?

MT2 is not approved by the FDA for any indication. It is not the same as afamelanotide (Scenesse), which is an FDA-approved implant for a specific rare photosensitivity disorder and is not interchangeable with compounded or research-grade MT2. People using MT2 sourced outside a licensed medical provider are using an unregulated compound with no verified purity, dosing consistency, or safety monitoring.

The "lasting tan" effect the creator describes is biologically plausible in principle. Persistent eumelanin after MT2 use has biological precedent based on what we know about melanocyte stimulation and cell turnover timelines. But it has not been confirmed in controlled human studies at seven-month post-cessation intervals. This is a case where the anecdote might be pointing at something real, but the creator is presenting a personal observation as if it's a documented finding. It isn't.

If you're considering MT2 or MT1 for cosmetic tanning, the absence of FDA approval and the lack of long-term safety data on melanocytic lesion activation should be part of that conversation with a licensed medical provider, not something you skip because a TikTok looked convincing.

Bottom line

The creator's core observation, that prior MT2 use may prime skin for easier tanning later, has partial biological plausibility but zero controlled clinical confirmation. The video normalizes unsupervised peptide use without addressing the documented risks. Credit where it's due: they're not making wild cure claims. But the safety gaps in this video are significant, and 11,000 viewers deserve to know them.